BBP-398 + sotorasib
Phase 1Terminated 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor, Adult
Conditions
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
Trial Timeline
Jul 6, 2022 → Aug 22, 2024
NCT ID
NCT05480865About BBP-398 + sotorasib
BBP-398 + sotorasib is a phase 1 stage product being developed by BridgeBio Pharma for Solid Tumor, Adult. The current trial status is terminated. This product is registered under clinical trial identifier NCT05480865. Target conditions include Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05480865 | Phase 1 | Terminated |
Competing Products
20 competing products in Solid Tumor, Adult